Goldman Sachs’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Goldman Sachs’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-715,700	Closed	-$2.15M	–	5690
2019 Q4	$2.15M	Buy	+715,700	New	+$1.86M	﹤0.01%	3597

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Goldman Sachs's BMY.RT Position: Q1 2021 in Review

Goldman Sachs sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 4,374,383 shares — an estimated $3.02M sold.

Goldman Sachs first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $22.2M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Goldman Sachs reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Goldman Sachs sold 4,374,383 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3.02M.
Goldman Sachs first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Goldman Sachs's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $22.2M in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.